Date published: 2026-5-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

CCDC139 Activators

CCDC139 Activators are a diverse group of chemical compounds that have the potential to enhance the functional activity of CCDC139 through different biochemical pathways. Forskolin and IBMX, for example, are known to increase intracellular cAMP levels, which in turn activates protein kinase A (PKA). If CCDC139 is a substrate for PKA or involved in cAMP-dependent signaling, these compounds could lead to its activation. Similarly, by increasing intracellular calcium levels, Ionomycin and A23187 could activate calcium-dependent signaling pathways that may involve CCDC139. PMA, a known activator of PKC, might enhance CCDC139 activity if PKC-dependent phosphorylation is part of its regulation. Moreover, Epigallocatechin gallate (EGCG) serves as a kinase inhibitor and could lead to the activation of CCDC139 by inhibiting kinases that otherwise negatively regulate the protein or its pathways.

Additionally, LY294002 and U0126, inhibitors of PI3K and MEK respectively, could indirectly activate CCDC139 by altering the PI3K/Akt and MAPK/ERK pathways, assuming CCDC139 activity is modulated by these pathways. SB203580, a p38 MAPK inhibitor, and Anisomycin, a JNK activator, may affect CCDC139 by either shifting signaling dynamics in favor of pathways that activate CCDC139 or byactivating JNK signaling, which CCDC139 could be a part of. Sphingosine-1-phosphate (S1P) binds to G protein-coupled receptors and initiates signaling cascades that could include CCDC139 if it is indeed involved in S1P-responsive pathways. Genistein, by inhibiting tyrosine kinases, may remove competitive inhibition from other pathways, potentially leading to the activation of CCDC139 if it is under the regulatory influence of tyrosine kinase signaling. Collectively, these chemical activators, through their targeted influence on cellular signaling pathways, offer a spectrum of mechanisms that could lead to the enhanced functional activity of CCDC139 without necessarily upregulating its expression or requiring direct interaction with the protein.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Ionomycin

56092-82-1sc-3592
sc-3592A
1 mg
5 mg
$78.00
$270.00
80
(4)

Ionomycin is a calcium ionophore that increases intracellular calcium levels. Elevated calcium can activate calcium-dependent signaling pathways, which may lead to the activation of CCDC139 if it is involved in such pathways.

PMA

16561-29-8sc-3576
sc-3576A
sc-3576B
sc-3576C
sc-3576D
1 mg
5 mg
10 mg
25 mg
100 mg
$41.00
$132.00
$214.00
$500.00
$948.00
119
(6)

PMA activates protein kinase C (PKC), which is involved in various signaling pathways. If CCDC139 is regulated by PKC-dependent phosphorylation, PMA may enhance its functional activity.

IBMX

28822-58-4sc-201188
sc-201188B
sc-201188A
200 mg
500 mg
1 g
$260.00
$350.00
$500.00
34
(1)

IBMX is a non-specific inhibitor of phosphodiesterases, which leads to increased cAMP levels. Through the same mechanism as Forskolin, IBMX could lead to the activation of CCDC139 if it is involved in cAMP/PKA-regulated pathways.

(−)-Epigallocatechin Gallate

989-51-5sc-200802
sc-200802A
sc-200802B
sc-200802C
sc-200802D
sc-200802E
10 mg
50 mg
100 mg
500 mg
1 g
10 g
$43.00
$73.00
$126.00
$243.00
$530.00
$1259.00
11
(1)

EGCG is a kinase inhibitor that may lead to the activation of CCDC139 by inhibiting kinases that negatively regulate CCDC139 or its associated pathways.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 is a PI3K inhibitor that could indirectly activate CCDC139 by altering signaling pathways that regulate CCDC139 activity, assuming it is influenced by PI3K/Akt signaling.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$64.00
$246.00
136
(2)

U0126 is a MEK inhibitor that may enhance CCDC139 activity by modulating the MAPK/ERK pathway, if CCDC139 is influenced by this pathway.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB203580 is a p38 MAPK inhibitor which may shift signaling dynamics in favor of pathways that activate CCDC139, provided it is associated with p38 MAPK signaling.

D-erythro-Sphingosine-1-phosphate

26993-30-6sc-201383
sc-201383D
sc-201383A
sc-201383B
sc-201383C
1 mg
2 mg
5 mg
10 mg
25 mg
$165.00
$322.00
$570.00
$907.00
$1727.00
7
(1)

S1P engages with G protein-coupled receptors to activate signaling cascades that could include CCDC139 activation if it participates in these pathways.

Anisomycin

22862-76-6sc-3524
sc-3524A
5 mg
50 mg
$99.00
$259.00
36
(2)

Anisomycin is a JNK activator that can influence the JNK signaling pathway, potentially leading to the activation of CCDC139 if it is regulated by JNK signaling.

A23187

52665-69-7sc-3591
sc-3591B
sc-3591A
sc-3591C
1 mg
5 mg
10 mg
25 mg
$55.00
$131.00
$203.00
$317.00
23
(1)

A23187 is a calcium ionophore that, similar to Ionomycin, raises intracellular calcium levels and may activate CCDC139 if it is part of calcium-dependent signaling processes.